JP2019529554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529554A5 JP2019529554A5 JP2019536698A JP2019536698A JP2019529554A5 JP 2019529554 A5 JP2019529554 A5 JP 2019529554A5 JP 2019536698 A JP2019536698 A JP 2019536698A JP 2019536698 A JP2019536698 A JP 2019536698A JP 2019529554 A5 JP2019529554 A5 JP 2019529554A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- met
- mutation
- pharmaceutical composition
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 29
- 230000035772 mutation Effects 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 5
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229960001292 cabozantinib Drugs 0.000 claims 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 1
- 229950005852 capmatinib Drugs 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950002846 ficlatuzumab Drugs 0.000 claims 1
- 229950008692 foretinib Drugs 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1616116.8 | 2016-09-22 | ||
| GBGB1616116.8A GB201616116D0 (en) | 2016-09-22 | 2016-09-22 | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| PCT/EP2017/073894 WO2018055029A1 (en) | 2016-09-22 | 2017-09-21 | Use of c-met inhibitors to treat cancers harbouring met mutations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529554A JP2019529554A (ja) | 2019-10-17 |
| JP2019529554A5 true JP2019529554A5 (enExample) | 2020-10-22 |
| JP7065858B2 JP7065858B2 (ja) | 2022-05-12 |
Family
ID=57539720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536698A Active JP7065858B2 (ja) | 2016-09-22 | 2017-09-21 | ＭＥＴ突然変異を宿すがんを治療するためのｃ－Ｍｅｔ阻害剤の使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190282570A1 (enExample) |
| EP (1) | EP3515418B1 (enExample) |
| JP (1) | JP7065858B2 (enExample) |
| CN (1) | CN109789108A (enExample) |
| CY (1) | CY1124668T1 (enExample) |
| DK (1) | DK3515418T3 (enExample) |
| ES (1) | ES2880085T3 (enExample) |
| GB (1) | GB201616116D0 (enExample) |
| HR (1) | HRP20210998T1 (enExample) |
| HU (1) | HUE054765T2 (enExample) |
| LT (1) | LT3515418T (enExample) |
| PL (1) | PL3515418T3 (enExample) |
| PT (1) | PT3515418T (enExample) |
| RS (1) | RS62084B1 (enExample) |
| SI (1) | SI3515418T1 (enExample) |
| SM (1) | SMT202100405T1 (enExample) |
| TW (1) | TWI784969B (enExample) |
| WO (1) | WO2018055029A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3881847A4 (en) * | 2018-11-14 | 2022-09-07 | Kanazawa Medical University | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIFFUSE STOMACH CANCER |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| RU2384331C2 (ru) | 2005-12-05 | 2010-03-20 | Пфайзер Продактс Инк. | Способ лечения аномального роста клеток |
| MX2008012485A (es) * | 2006-03-30 | 2008-10-10 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de c-met. |
| BR112012016129B1 (pt) | 2009-12-31 | 2020-11-03 | Hutchison Medipharma Limited | composto, composição e uso dos ditos compostos |
-
2016
- 2016-09-22 GB GBGB1616116.8A patent/GB201616116D0/en not_active Ceased
-
2017
- 2017-09-21 PL PL17777211T patent/PL3515418T3/pl unknown
- 2017-09-21 TW TW106132358A patent/TWI784969B/zh active
- 2017-09-21 CN CN201780057297.7A patent/CN109789108A/zh active Pending
- 2017-09-21 HR HRP20210998TT patent/HRP20210998T1/hr unknown
- 2017-09-21 PT PT177772118T patent/PT3515418T/pt unknown
- 2017-09-21 US US16/335,697 patent/US20190282570A1/en not_active Abandoned
- 2017-09-21 JP JP2019536698A patent/JP7065858B2/ja active Active
- 2017-09-21 ES ES17777211T patent/ES2880085T3/es active Active
- 2017-09-21 DK DK17777211.8T patent/DK3515418T3/da active
- 2017-09-21 SM SM20210405T patent/SMT202100405T1/it unknown
- 2017-09-21 SI SI201730818T patent/SI3515418T1/sl unknown
- 2017-09-21 RS RS20210854A patent/RS62084B1/sr unknown
- 2017-09-21 EP EP17777211.8A patent/EP3515418B1/en active Active
- 2017-09-21 HU HUE17777211A patent/HUE054765T2/hu unknown
- 2017-09-21 WO PCT/EP2017/073894 patent/WO2018055029A1/en not_active Ceased
- 2017-09-21 LT LTEP17777211.8T patent/LT3515418T/lt unknown
-
2021
- 2021-07-13 CY CY20211100624T patent/CY1124668T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523397A5 (enExample) | ||
| ZA202103587B (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| JP2016163571A5 (enExample) | ||
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| JP2015536964A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| JP2017504611A5 (enExample) | ||
| JP2015532296A5 (enExample) | ||
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2014525454A5 (enExample) | ||
| CY1106430T1 (el) | Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο | |
| NZ784949A (en) | Ripretinib for treating gastrointestinal stromal tumors | |
| JP2013541583A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| JP2015527374A5 (enExample) | ||
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| HRP20161147T1 (hr) | Farmaceutski sastav i postupak njegove proizvodnje | |
| JP2015507020A5 (enExample) | ||
| PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| JP2021505669A5 (enExample) | ||
| JP2021504384A5 (enExample) | ||
| RU2014113941A (ru) | Суспензия для перорального введения | |
| JP2019529554A5 (enExample) |